Samsung BioLogics

Samsung Biologics, founded in April 2011 and headquartered in Incheon, South Korea, is a leading contract development and manufacturing organization (CDMO) in the biopharmaceutical industry. Established by key players within the Samsung Group and Quintiles Transnational Corp, the company aims to provide high-quality, innovative, and efficient services to its global clients, with Europe and the United States accounting for 90% of its revenue. Samsung Biologics offers comprehensive development and manufacturing services, spanning from cell line development to final commercial production, and boasts a total production capacity of 604,000 liters, one of the largest worldwide. The company's CDMO services represent 72.4% of its revenue, while the remainder comes from its subsidiary, Samsung Bioepis, which focuses on developing and manufacturing biosimilars. The organization emphasizes strict adherence to quality and regulatory standards, ensuring compliance with international cGMP requirements. Dr. Tae Han Kim, the Chief Executive Officer, has played a significant role in the company’s expansion and operational excellence since joining Samsung in 1979.